Business

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

CNBC·Oct 24, 2026 · 9:30 AM CT
Read the original at CNBC
Readthrough summary

Full late-stage trial results released Saturday show that adding Amgen's Imdelltra to AstraZeneca's immunotherapy Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months on Imfinzi alone, when the combo was used as maintenance therapy after initial treatment.

Summary written by Readthrough from the original article. The full story, with photos and any updates, is at CNBC.

Read the original at CNBC

More Business

HM Treasury·

Chancellor unveils Britain’s ambitious plan for AI

UK Chancellor plans a major AI package as part of next week's Budget, aiming to spread AI opportunities across the country, scale up British AI firms and guard against hostile threats. HM Treasury says the plans include hundreds of millions in investment, among them £10 million a year to study how AI will reshape jobs and industry.

HM Treasury·

Jackdaw gas field gets green light

The UK Energy Secretary cleared the way for gas production at the Jackdaw field, which could start supplying homes by the end of this month and lift domestic gas output by about 6% at peak. The Chancellor also announced a new Energy Wealth Fund with a £2 billion downpayment.

Fox Business·

GOP firebrand Luna joins California Democrat Khanna in surprising push to overhaul workplace rules

Rep. Anna Paulina Luna (R-Fla.) and Rep. Ro Khanna (D-Calif.) have jointly introduced the Workers' Right to Compete Act, which would ban non-compete agreements for employees earning less than $100,000 a year. The bill would also void existing non-competes within 30 days of passage. Both lawmakers argue the contracts hold back wages, job mobility and economic growth.

SEC press releases·

SEC Announces Fiscal Year 2027 Examination Priorities

The SEC's Division of Examinations released its fiscal 2027 examination priorities, listing the areas it sees as the biggest risks to investors and market integrity. The division also said it wants to be more accessible to registrants during exams.